"1,100 Linux processor configuration combines unique software
and operational IT techniques with world-leading science to
accelerate drug discovery through the analysis of protein
"Inpharmatica, a leading innovator in the application of
structural bioinformatics in pharmaceutical research, announced
today that it has more than doubled the power of its in-house
computer facilities. Correctly-used computer power is an essential
part of present and future techniques involved in discovering the
drugs of tomorrow and in analysing the enormous amounts of data now
generated by the Human Genome Project. Inpharmatica's 1,100
processor system is the most powerful commercial installation in
Europe dedicated to bioinformatics, the use of computer techniques
in drug discovery."
"This substantial upgrade propels Inpharmatica into an even
stronger position in the provision of up-to-date, comprehensive
and, above all, useful information on the human proteome," said Dr
Malcolm Weir, CEO at Inpharmatica. "Our Biopendium information
resource that relates protein sequences to their structure and
function is now able to incorporate all available genome sequence
data for analysis. We can update it more frequently and carry out
more and better customized projects for our clients."
"Historically, companies wanting to do large scale
processing-intensive computing have had to rely on specialist high
performance computing vendors with high-cost proprietary
solutions," said Pat Leach, IT director at Inpharmatica. "The use
of Linux and the low cost of standard PC components has enabled
Inpharmatica to achieve `more for less'."
Some of the products that appear on this site are from companies from which QuinStreet receives compensation. This compensation may impact how and where products appear on this site including, for example, the order in which they appear. QuinStreet does not include all companies or all types of products available in the marketplace.